Matteo Lambertini, MD PhD is leading the most innovative research efforts to provide clear data about fertility preservation techniques and clinical outcomes in women with cancer.
Sadly, this topic is still a taboo.

As a woman and as oncologist, I feel so grateful.

Keep shining, Matte!

Non sono ancora chiare le regioni per cui, negli ultimi anni, i tumori tra le donne giovani sono in aumento. Stili di vita sbagliati? Fumo? Cause genetiche? Non lo sappiamo, ma proprio per questo è importante la #prevenzione : così stamani, per Fondazione AIRC per la ricerca sul cancro, l'oncologo Matteo Lambertini, MD PhD…

Oggi, in Italia, se 2 donne su 3 sono vive a 5 anni da una diagnosi di cancro è solo grazie alla ricerca. Stamani, alle 11.30 su radio3, la campagna che Fondazione AIRC per la ricerca sul cancro sostiene ogni anno con la vendita di #azalee . A seguire la 14^ puntata del #MuseodeiFuturi : la parola chiave è…

Grazie mille per l’opportunità di parlare della nostra ricerca sostenuta da Fondazione AIRC per la ricerca sul cancro nel campo dell’oncofertiltà rivolta alle giovani donne affette da neoplasia mammaria

Università di Genova Ospedale San Martino Genova

📣La X-DOL Academy-First Edition è un progetto di educazione e formazione dedicato ai giovani oncologi e patologi sull’utilizzo di social media, ed in particolare di X, nella comunicazione medica.

🗣️FACULTY:
Saverio Cinieri - Saverio Cinieri
Massimo Di Maio - Massimo Di Maio

The OncoAlert🚨ROUND UP
Covering May 2-8, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

✅ The Lancet Commission on #ProstateCancer
thelancet.com/journals/lance…

✅DESTINY-PanTumor01
thelancet.com/journals/lanon…

✅MONARCH3 🦋in #BreastCancer

The MONARCH 3 trial
Addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for hormone receptor-positive, 🧬HER2-negative advanced #BreastCancer

✅ Significantly improved PFS and showed clinically meaningful improvement in OS

➡️ particularly…

The OncoAlert🚨NEWSLETTER OUT
Covering May 2-8, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

✅ The Lancet Commission on #ProstateCancer
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative

Out by our partner journal ACS Journal Cancer American Cancer Society 🇺🇸

OncoFertility🤰🏾
population-based study reveals that non-Hispanic Black adolescents and young adults (AYAs) with cancer are:

➡️ less likely to have live births after cancer compared to other racial/ethnic groups…

📣 breast cancer colleagues! very relevant and practical question: what is the performance of everolimus + ET after CDK4/6 inhibitors in MBC?

I’m proud to share with you our recently published Spanish RWE study with more than 160 pts in this scenario 👇🏻

link.springer.com/article/10.100…

163P - Characterization of HER2-Low Breast Cancer in Young Women with Germline BRCA1/2 Pathogenetic Variants: Results of a Large International Retrospective Cohort Study (ID 364)

Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺 Matteo Lambertini, MD PhD

What is the impact of HER2-low disease in young women with germline…

ESMO - Eur. Oncology Breast 2024 in Berlin is approaching!

Excited to share highlights from my Lab/team with 14 impactful studies being presented.

Stay tuned!

👇👇👇

Hospital Clínic IDIBAPS Universitat de Barcelona REVEAL GENOMICS #ClinicCancerCenter

🎉👏Delighted to announce that our team has secured 2 out of the 20 ESMO Merit Travel Grants for the ESMO Breast Cancer 2024 conference! ESMO - Eur. Oncology

Guillermo Villacampa
1MO - HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with…

The ASCENT study out on npj Journals
Showing that sacituzumab govitecan 💉offers:

✅significant improvements📈 in PFS and OS compared to standard chemotherapy🧪 in specific subgroups of metastatic triple-negative #BreastCancer patients

➡️Manageable safety profile, affirming its…

Is #OncoFertility care equitable? In a Texas study led by Andrea Betts, PhD MPH, Black women diagnosed with cancer as adolescents and young adults were less likely to have a live birth after cancer than women of other races.

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

OncoAlert Abby Rosenberg, MD, MS, MA #ayacsm

Thank you Matteo Lambertini, MD PhD for your kind words and for giving me the opportunity to achieve this amazing accomplishment 🙏🏼

Grateful to Conquer Cancer, the ASCO Foundation for selecting me as one of the 140 recipients of the ASCO Merit Award 2024!
See you soon #Chicago #ASCO24

The power source of an academic department are the fellows & junior faculty. They should be nurtured, stimulated and their efforts and successes promoted. The seniors role is to make juniors shine.
Matteo Lambertini, MD PhD is an example of great mentorship. Congrats Luca Arecco, MD! Oncology Division - Geneva University Hospital

Great to see our super Ospedale San Martino Genova Università di Genova fellow Luca Arecco, MD (now research fellow at Institut Jules Bordet Instituut with Evandro de Azambuja, MD, PhD) in the list…really grateful to Conquer Cancer, the ASCO Foundation ASCO for supporting and motivating many young oncologists!
So much looking forward to #ASCO24
OncoAlert

The OncoAlert 🚨Network Warmly extends its congratulations to Two of our Distinguished Faculty, part of our Founding faculty and ESMO - Eur. Oncology Presidents:

⚕️ Solange Peters 🇨🇭 from CHUV / Centre hospitalier universitaire vaudois
⚕️ FabriceAndre 🇫🇷 from Gustave Roussy

Named Giants of Cancer Care, an award that…

Out on JAMA Oncology 🚨
Cohort study found that bilateral oophorectomy in women with BRCA1 or BRCA2 🧬sequence variations was associated with;

➡️significant reduction📉 in all-cause mortality, underscoring the procedure's preventive benefit in this high-risk population‼️…